At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed limited-stage small cell lung cancer
- ✓Measurable or non-measurable disease documented by CT, MRI, or X-ray within 28 days (measurable) or 42 days (non-measurable) prior to registration
- ✓Creatinine clearance ≥50 cc/min or serum creatinine <1.5 mg/dL if calculated CrCl used, within 28 days prior to registration
- ✓ANC ≥1,500/μL within 28 days prior to registration
- ✕Any brain metastases; brain CT or MRI required within 42 days prior to registration
- ✕Malignant pericardial or pleural effusions (cytologically positive or exudative not attributable to other etiologies)
- ✕Prior chemotherapy or biologic therapy for small cell lung cancer
- ✕Prior thoracic or neck radiation for any reason
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating tirapazamine, cisplatin, and 3 other interventions for Limited Stage Small Cell Lung Cancer. Completed, enrolled 72 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving tirapazamine together with cisplatin, etoposide, and radiation therapy works in treating patients with limited-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tirapazamine may make the tumor cells more sensitive to chemotherapy and radiation therapy. Combining chemotherapy and radiation therapy with tirapazamine may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Undergo radiation therapy
Correlative studies